The first oral GLP-1 weight loss medication has arrived on American pharmacy shelves, and early signs suggest strong demand. Novo Nordisk's Wegovy pill—the same active ingredient as the blockbuster injection in a once-daily tablet form—hit 3,071 U.S. prescriptions in its first four days after launch, according to IQVIA data. For a company seeking redemption after its worst stock year on record, the numbers offer cautious optimism.

Novo Nordisk's American depositary receipts rose on the news, trading near $52 after touching lows of $43 during the December selloff. The stock remains roughly 45% below its 2025 highs, but the pill launch represents the beginning of what the company hopes will be a new growth chapter.

Why the Pill Matters

The injectable versions of Wegovy and Ozempic transformed obesity treatment but came with limitations that constrained their market. Many patients resist self-injection. Supply shortages plagued the rollout. Insurance coverage remained inconsistent. The pill format potentially addresses all three issues.

Key advantages of oral Wegovy:

  • No injection required: Removes a major psychological barrier for many patients
  • Easier administration: Once-daily tablet versus weekly injection
  • Manufacturing scalability: Pills are generally easier to produce at volume than injectable formulations
  • Potential cost advantages: Simpler production could eventually support lower pricing

The pill uses a novel delivery technology that protects the active ingredient (semaglutide) from stomach acid and enables absorption through the intestinal lining. Clinical trials showed weight loss comparable to the injectable version—approximately 15% of body weight over 68 weeks.

The Competitive Landscape

Novo Nordisk's pill launch comes as competition in the obesity market intensifies. Eli Lilly's injectable Zepbound has taken significant market share, and the Indianapolis-based rival is developing its own oral obesity medication, Orforglipron, expected to seek FDA approval around March 2026.

The timing gives Novo Nordisk several months of near-monopoly in oral GLP-1 obesity therapy—a window the company is moving aggressively to exploit. Amazon's pharmacy service has already begun offering Wegovy pills, expanding distribution channels beyond traditional pharmacies.

"The marketable development for Wegovy and Ozempic is a must-win battle for Novo's new CEO and board. The oral launch is their first major opportunity to reset the narrative."

— Healthcare analyst at Morningstar

Novo Nordisk's Difficult 2025

Context matters for understanding why this launch is so important. Novo Nordisk's stock fell 40% in 2025—its worst year on record since trading began on the Copenhagen stock exchange over three decades ago. Multiple factors contributed:

  • Guidance cuts: The company lowered financial forecasts three times as growth slowed
  • Eli Lilly competition: Zepbound captured market share faster than expected
  • Generic threats: Compounding pharmacies began offering unauthorized copies at lower prices
  • Leadership changes: Management reshuffling added uncertainty
  • Multiple compression: Investors questioned whether the obesity boom could sustain premium valuations

The result: Novo Nordisk trades at roughly 14x forward earnings, about half its historical average multiple of 27x. For long-term believers in the obesity treatment thesis, that compression represents opportunity. For skeptics, it reflects appropriate repricing of an overhyped story.

The Broader Obesity Market

Despite Novo Nordisk's specific challenges, the obesity treatment market continues expanding. Current estimates suggest over 40% of American adults meet clinical criteria for obesity, creating enormous potential demand. Yet only a small fraction currently uses GLP-1 medications.

Key market dynamics:

  • Insurance coverage expanding: More payers covering obesity medications, though restrictions remain
  • Medicare Part D inclusion: Recent policy changes allow coverage for some obesity indications
  • Corporate wellness programs: Employers increasingly offering GLP-1 coverage as preventive care
  • International expansion: Demand growing in Europe and Asia

Goldman Sachs estimates the global obesity drug market could reach $100 billion annually by 2030, up from approximately $25 billion today. Even if Novo Nordisk loses market share, a larger pie could still mean growing revenue.

Investment Considerations

For investors evaluating Novo Nordisk, the thesis centers on execution and competitive dynamics:

  • Bull case: Oral Wegovy succeeds, supply issues resolve, international markets expand, multiple re-rates toward historical averages
  • Bear case: Eli Lilly dominates, generic competition accelerates, growth disappoints, multiple remains compressed
  • Valuation: At 14x earnings, significant pessimism already priced in—but could get worse if execution fails

Analysts maintain mixed views. The consensus price target of $81.63 implies significant upside, but the range spans from $31 (BTIG) to $160 (Cantor Fitzgerald)—reflecting genuine uncertainty about the company's trajectory.

Earnings Ahead

Novo Nordisk reports full-year 2025 earnings on February 4th before Copenhagen trading opens. The report will provide updated guidance for 2026 and likely include commentary on the oral Wegovy launch. Morningstar's current forecast assumes roughly 2% sales decline in 2026—a sharp reversal from years of double-digit growth.

For a company accustomed to being the growth darling of European healthcare, 2026 represents a reset. The oral Wegovy launch won't single-handedly restore former glory, but it demonstrates Novo Nordisk's ability to innovate and adapt. In the fiercely competitive obesity drug wars, that capability may prove more valuable than any single product.